CRS MANAGEMENT
AT INDIAN CAR-T CENTRES

Cytokine release syndrome (CRS) occurs when CAR-T cells rapidly expand and release large amounts of inflammatory cytokines — particularly IL-6, IFN-γ, and IL-2 — as they engage tumour cells. It is the most common serious toxicity of CAR-T therapy.

“India's biosimilar tocilizumab ecosystem means grade 2–3 CRS is treated without the $8,000+ drug cost that patients in the USA face — it is included in the treatment budget.”

• Why CRS Happens

  As CAR-T cells recognise CD19+ tumour cells, they activate and proliferate rapidly. This activation releases cytokines that cause systemic inflammation — fever, hypotension, and in severe cases, multi-organ dysfunction. Higher tumour burden at infusion is associated with more severe CRS.

• When CRS Typically Occurs

  CRS onset is usually within 1–14 days post-infusion, peaking around Day 3–7. Grade 1–2 CRS (fever, mild hypotension) is common and generally self-limiting. Grade 3–4 CRS (severe hypotension, oxygen requirement, ICU admission) is uncommon with NexCAR19 (6% rate).

• NexCAR19 CRS Profile: Better Than Western Products

  NexCAR19's 6% grade 3+ CRS rate in the pivotal trial is significantly lower than Kymriah's ELIANA trial (22% grade 3+ CRS) and Yescarta's ZUMA-1 trial (~13% grade 3+). This difference may reflect the CAR construct design or patient management protocols at Indian centres.

• ASTCT 2019 Grading Criteria

  All major Indian CAR-T centres use the ASTCT (American Society for Transplantation and Cellular Therapy) 2019 CRS consensus grading. Grade 1: fever only. Grade 2: fever + hypotension responsive to fluids or low-dose vasopressors, or hypoxia on low-flow O2. Grade 3: high-dose vasopressors or high-flow O2. Grade 4: life-threatening.

Indian centres follow a structured CRS management protocol aligned with ASTCT guidelines. Tocilizumab biosimilar is the cornerstone of grade 2+ CRS management.

1. 1

   Grade 1 CRS: Monitoring and Antipyretics

   Fever without organ dysfunction. Managed with antipyretics (paracetamol), aggressive IV hydration, and close monitoring every 4–8 hours. No tocilizumab required at this grade.

2. 2

   Grade 2 CRS: Tocilizumab Initiated

   Tocilizumab (anti-IL-6R) 8 mg/kg IV given for grade 2 CRS (hypotension requiring fluids or low-dose vasopressors, or O2 requirement up to 6L/min). Biosimilar tocilizumab cost: $200–400 per dose at Indian centres.

3. 3

   Grade 3 CRS: Steroid Addition

   High-dose vasopressors or high-flow oxygen. Methylprednisolone 1 mg/kg or dexamethasone 10 mg IV added to tocilizumab. ICU transfer initiated. Second dose tocilizumab if no response at 12–24 hours.

4. 4

   Grade 4 CRS: Intensive Management

   Life-threatening organ dysfunction. High-dose steroids, multi-vasopressor support, ICU. Second-line agents (siltuximab, ruxolitinib) considered if refractory to tocilizumab + steroids. Rare with NexCAR19.

5. 5

   Recovery: Most CRS Grade 1–2 Resolves in 3–7 Days

   With appropriate management, most grade 1–2 CRS episodes resolve within 3–7 days. Patients are stepped down from ICU to ward once vasopressors and supplemental oxygen are discontinued.

• $200–400Tocilizumab Biosimilar IndiaPer dose of biosimilar tocilizumab (Actemra biosimilar) at Indian CAR-T centres.
• $2,000+Branded Tocilizumab USAPer-dose cost of branded Actemra (tocilizumab) in the United States before insurance.
• 6%NexCAR19 Grade 3+ CRSSevere CRS rate — typically requiring 1–2 doses of tocilizumab and steroid support.
• 3–7 daysCRS ResolutionTypical resolution time for grade 1–2 CRS with appropriate supportive care.

Patients and families frequently ask whether Indian centres have the ICU infrastructure to manage severe CRS. All approved NexCAR19 and Kymriah centres maintain dedicated haematology/oncology ICU capability.

• Tata Memorial Centre — Dedicated Haematology ICU

  TMC has a dedicated haematology and BMT intensive care unit with haematologists trained in CAR-T toxicity management on 24-hour call. This is the highest-volume CAR-T centre in India with the most direct experience managing NexCAR19-related CRS.

• Apollo, Manipal, and Fortis — Multi-Disciplinary ICU

  Apollo, Manipal, and Fortis hospitals all have multi-disciplinary ICUs accredited for complex haematology care. These hospitals typically have cardiologists, intensivists, and nephrologists embedded in the ICU team — relevant for grade 3–4 CRS management requiring multi-organ support.

Understand the full treatment timeline, ICANS management, and access pathways.

Frequently Asked Questions: CRS Management in India